Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRL-1 PK in Epilepsy Subjects
NCT02724423Phase 1Completed
- Sponsor
- Neurelis
- Start
- Jun 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of diazepam nasal spray in Acute repetitive seizures (ARS) (2 arms), sponsored by Neurelis. Primary endpoint: Maximum Plasma Concentration at 6 hours. Started Jun 2016; status: completed.
02
Drugs
diazepam nasal spray
03
Conditions
Acute repetitive seizures (ARS)
Beyond the preview
Go deeper on NCT02724423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724423.